

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Accord Healthcare (serplulimab)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
 Asthma and Lung UK Black Health Agency for Equality 	 Board of Community Health Councils in Wales
Cancer Black Care	British National Formulary
	-
Cancer Equality	Care Quality Commission
Helen Rollason Cancer Charity	Department of Health, Social Services and Bublic Sefety for Northern Iroland
Independent Cancer Patients Voice	and Public Safety for Northern Ireland
Macmillan Cancer Support	Healthcare Improvement Scotland
Maggie's Centres	Medicines and Healthcare products
Marie Curie	Regulatory Agency
Oncogene-Driven Lung Cancer	National Association of Primary Care
Patient Alliance UK	National Pharmacy Association
Roy Castle Lung Cancer Foundation	NHS Confederation
Ruth Strauss Foundation	Scottish Medicines Consortium
South Asian Health Foundation	Welsh Government
Specialised Healthcare Alliance	 Welsh Health Specialised Services
Tenovus Cancer Care	Committee
UK Lung Cancer Coalition	
	Possible comparator companies
Healthcare professional groups	 Accord Healthcare (cisplatin,
Association of Anaesthetists	carboplatin, gemcitabine)
Association of Cancer Physicians	 Consilient Health (carboplatin)
Association of Respiratory Nurse Specialists	 Hospira UK (cisplatin, carboplatin, gemcitabine)
 Association of Surgeons of Great 	Roche Products (atezolizumab)
Britain and Ireland	 Sandoz (cisplatin)
 British Geriatrics Society 	 Sun Pharmaceuticals (gemcitabine)
 British Institute of Radiology 	(9
 British Oncology Pharmacy 	Relevant research groups
Association	Cochrane Lung Cancer Group
 British Psychosocial Oncology Society 	Genomics England
 British Psychosocial Oncology Society British Society of Interventional 	 Institute of Cancer Research
	 MRC Clinical Trials Unit
Radiology	

Provisional stakeholder list for the evaluation of serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346 Issue date: September 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Thoracic Oncology Group British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal College of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society 	 National Institute for Health Research <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.